367 related articles for article (PubMed ID: 12498738)
1. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
Santos DL; Moreno AJ; Leino RL; Froberg MK; Wallace KB
Toxicol Appl Pharmacol; 2002 Dec; 185(3):218-27. PubMed ID: 12498738
[TBL] [Abstract][Full Text] [Related]
2. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.
Oliveira PJ; Bjork JA; Santos MS; Leino RL; Froberg MK; Moreno AJ; Wallace KB
Toxicol Appl Pharmacol; 2004 Oct; 200(2):159-68. PubMed ID: 15476868
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
Pereira GC; Silva AM; Diogo CV; Carvalho FS; Monteiro P; Oliveira PJ
Curr Pharm Des; 2011; 17(20):2113-29. PubMed ID: 21718248
[TBL] [Abstract][Full Text] [Related]
4. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria?
Oliveira PJ; Gonçalves L; Monteiro P; Providencia LA; Moreno AJ
Curr Vasc Pharmacol; 2005 Apr; 3(2):147-58. PubMed ID: 15853634
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol: just another Beta-blocker or a powerful cardioprotector?
Carreira RS; Monteiro P; Gon Alves LM; Providência LA
Cardiovasc Hematol Disord Drug Targets; 2006 Dec; 6(4):257-66. PubMed ID: 17378771
[TBL] [Abstract][Full Text] [Related]
6. Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
Chen YL; Chung SY; Chai HT; Chen CH; Liu CF; Chen YL; Huang TH; Zhen YY; Sung PH; Sun CK; Chua S; Lu HI; Lee FY; Sheu JJ; Yip HK
J Pharmacol Exp Ther; 2015 Dec; 355(3):516-27. PubMed ID: 26511374
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats.
Matsui H; Morishima I; Numaguchi Y; Toki Y; Okumura K; Hayakawa T
Life Sci; 1999; 65(12):1265-74. PubMed ID: 10503942
[TBL] [Abstract][Full Text] [Related]
8. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction.
Berthiaume JM; Oliveira PJ; Fariss MW; Wallace KB
Cardiovasc Toxicol; 2005; 5(3):257-67. PubMed ID: 16244371
[TBL] [Abstract][Full Text] [Related]
9. Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol.
Armstrong SC
J Mol Cell Cardiol; 2004 Oct; 37(4):817-21. PubMed ID: 15380672
[No Abstract] [Full Text] [Related]
10. Carvedilol reduces mitochondrial damage induced by hypoxanthine/xanthine oxidase: relevance to hypoxia/reoxygenation injury.
Oliveira PJ; Rolo AP; Palmeira CM; Moreno AJ
Cardiovasc Toxicol; 2001; 1(3):205-13. PubMed ID: 12213973
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol inhibits mitochondrial complex I and induces resistance to H2O2 -mediated oxidative insult in H9C2 myocardial cells.
Sgobbo P; Pacelli C; Grattagliano I; Villani G; Cocco T
Biochim Biophys Acta; 2007 Mar; 1767(3):222-32. PubMed ID: 17346667
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria.
Kametani R; Miura T; Harada N; Shibuya M; Wang R; Tan H; Fukagawa Y; Kawamura S; Matsuzaki M
Circ J; 2006 Mar; 70(3):321-6. PubMed ID: 16501300
[TBL] [Abstract][Full Text] [Related]
13. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.
Spallarossa P; Garibaldi S; Altieri P; Fabbi P; Manca V; Nasti S; Rossettin P; Ghigliotti G; Ballestrero A; Patrone F; Barsotti A; Brunelli C
J Mol Cell Cardiol; 2004 Oct; 37(4):837-46. PubMed ID: 15380674
[TBL] [Abstract][Full Text] [Related]
14. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function.
Oliveira PJ; Rolo AP; Sardão VA; Monteiro P; Gonçalves L; Providência LA; Palmeira CM; Moreno AJ
Rev Port Cardiol; 2004 Oct; 23(10):1291-8. PubMed ID: 15641294
[TBL] [Abstract][Full Text] [Related]
15. Effects of carvedilol on isolated heart mitochondria: evidence for a protonophoretic mechanism.
Oliveira PJ; Marques MP; Batista de Carvalho LA; Moreno AJ
Biochem Biophys Res Commun; 2000 Sep; 276(1):82-7. PubMed ID: 11006086
[TBL] [Abstract][Full Text] [Related]
16. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration.
Solem LE; Henry TR; Wallace KB
Toxicol Appl Pharmacol; 1994 Dec; 129(2):214-22. PubMed ID: 7527602
[TBL] [Abstract][Full Text] [Related]
17. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy.
Lebrecht D; Kirschner J; Geist A; Haberstroh J; Walker UA
Cardiovasc Pathol; 2010; 19(5):e167-74. PubMed ID: 19747854
[TBL] [Abstract][Full Text] [Related]
18. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol and antioxidant proteins in a type I diabetes animal model.
Diogo CV; Deus CM; Lebiedzinska-Arciszewska M; Wojtala A; Wieckowski MR; Oliveira PJ
Eur J Clin Invest; 2017 Jan; 47(1):19-29. PubMed ID: 27805735
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvedilol and its analog BM-910228.
Santos DJ; Moreno AJ
Biochem Pharmacol; 2001 Jan; 61(2):155-64. PubMed ID: 11163330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
